Get the Stockscreener App
18.79
2.97%
-0.60
Nurix Therapeutics Inc stock is traded at $18.79, with a volume of 364.28K.
It is down -2.97% in the last 24 hours and down -2.46% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$19.39
Open:
$19.29
24h Volume:
364.28K
Relative Volume:
0.21
Market Cap:
$1.91B
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-6.5017
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-2.06%
1M Performance:
-2.46%
6M Performance:
+61.78%
1Y Performance:
-5.74%
1-Day Range:
$18.67
$19.57
1-Week Range:
$18.11
$20.18
52-Week Range:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
18.82 | 1.97B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.37 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.63 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
821.21 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.64 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.26 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock - Investing.com
Nurix Therapeutics (NRIX) to Release Earnings on Tuesday - MarketBeat
Market Rankings: What is the next catalyst for Nurix Therapeutics IncJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know - sharewise.com
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The AI Journal
Aug Fed Impact: Is Contango Ore Inc attractive for institutional investorsJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
BTIG reiterates Buy rating on Nurix stock with $30 price target - Investing.com UK
Sectors Review: Is Nurix Therapeutics Inc a stock for growth or value investorsJuly 2025 Movers & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Volume Summary: Why Nurix Therapeutics Inc. stock could outperform in 2025 - Bộ Nội Vụ
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials - Investing.com Nigeria
Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story? - Sahm
NRIX: Bexabrutadeg shows best-in-class potential in CLL, driving pivotal trials and pipeline expansion - TradingView — Track All Markets
Nurix Therapeutics, Inc. Outlines 2026 Goals and Objectives - TradingView — Track All Markets
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - Investing News Network
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha
Inside Nurix's push to test a new cancer and autoimmune drug in 2026 - Stock Titan
Published on: 2026-01-10 21:09:42 - ulpravda.ru
Why retail investors pile into Nurix Therapeutics Inc. stockEarnings Growth Report & Fast Entry and Exit Trade Plans - ulpravda.ru
Aug Patterns: Why Nurix Therapeutics Inc. stock appeals to analystsPortfolio Gains Summary & Daily Stock Momentum Reports - Улправда
How Nurix Therapeutics Inc. stock compares to market leadersPortfolio Profit Report & Low Risk Entry Point Guides - ulpravda.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Sahm
Morgan Stanley Upgrades Nurix Therapeutics (NRIX) - Nasdaq
Dow Theory LettersNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Detailed Stock Data - FinancialContent
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Should I hold or sell Nurix Therapeutics Inc. stock in 20252026 world cup usa national team round of 32 goalkeepers high defensive line winner prediction statistical analysis - ulpravda.ru
User | ricentral.comNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Stock Quote - FinancialContent
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
NRIX Stock Price, Forecast & Analysis | NURIX THERAPEUTICS INC (NASDAQ:NRIX) - Chartmill
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):